Is AQST or URGN more profitable?

Urogen Pharma has a net margin of -51.73% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% Urogen Pharma -51.73% N/A -43.79%

Does the media favor AQST or URGN?

In the previous week, Urogen Pharma had 20 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 22 mentions for Urogen Pharma and 2 mentions for Aquestive Therapeutics. Urogen Pharma's average media sentiment score of 0.48 beat Aquestive Therapeutics' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Urogen Pharma 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ANIP or AQST?

In the previous week, ANI Pharmaceuticals had 21 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 2 mentions for Aquestive Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.67 beat Aquestive Therapeutics' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ANI Pharmaceuticals 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer OCUL or AQST?

In the previous week, Ocular Therapeutix had 17 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 19 mentions for Ocular Therapeutix and 2 mentions for Aquestive Therapeutics. Ocular Therapeutix's average media sentiment score of 0.02 beat Aquestive Therapeutics' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, AQST or TRLV?

Trulieve Cannabis has lower revenue, but higher earnings than Aquestive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aquestive Therapeutics $44.54M 12.35 -$83.78M -$0.61 N/A Trulieve Cannabis N/A N/A N/A N/A N/A

Is AQST or TRLV more profitable?

Trulieve Cannabis has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% Trulieve Cannabis N/A N/A N/A

Does the media prefer AQST or TRLV?

In the previous week, Trulieve Cannabis had 12 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 14 mentions for Trulieve Cannabis and 2 mentions for Aquestive Therapeutics. Trulieve Cannabis' average media sentiment score of 0.05 beat Aquestive Therapeutics' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Trulieve Cannabis 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 4 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to INVA or AQST?

In the previous week, Innoviva had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Innoviva and 2 mentions for Aquestive Therapeutics. Innoviva's average media sentiment score of 0.17 beat Aquestive Therapeutics' score of 0.00 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aquestive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Aquestive Therapeutics (AQST) Competitors

$4.50 +0.56 (+14.09%)

As of 12:23 PM Eastern

Compare

AQST vs. URGN, ANIP, OCUL, TRLV, and INVA

Should you buy Aquestive Therapeutics stock or one of its competitors? MarketBeat compares Aquestive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aquestive Therapeutics include Urogen Pharma (URGN), ANI Pharmaceuticals (ANIP), Ocular Therapeutix (OCUL), Trulieve Cannabis (TRLV), and Innoviva (INVA). These companies are all part of the "pharmaceuticals" industry.

How does Aquestive Therapeutics compare to Urogen Pharma?

Aquestive Therapeutics (NASDAQ:AQST) and Urogen Pharma (NASDAQ:URGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk.

In the previous week, Urogen Pharma had 20 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 22 mentions for Urogen Pharma and 2 mentions for Aquestive Therapeutics. Urogen Pharma's average media sentiment score of 0.48 beat Aquestive Therapeutics' score of 0.00 indicating that Urogen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Urogen Pharma	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Urogen Pharma has a net margin of -51.73% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Urogen Pharma	-51.73%	N/A	-43.79%

Aquestive Therapeutics has higher earnings, but lower revenue than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	12.35	-$83.78M	-$0.61	N/A
Urogen Pharma	$109.79M	20.72	-$153.49M	-$1.98	N/A

32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Urogen Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aquestive Therapeutics currently has a consensus price target of $8.50, suggesting a potential upside of 93.84%. Urogen Pharma has a consensus price target of $48.78, suggesting a potential upside of 4.83%. Given Aquestive Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aquestive Therapeutics is more favorable than Urogen Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Urogen Pharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Summary

Urogen Pharma beats Aquestive Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Aquestive Therapeutics compare to ANI Pharmaceuticals?

ANI Pharmaceuticals (NASDAQ:ANIP) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

In the previous week, ANI Pharmaceuticals had 21 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 23 mentions for ANI Pharmaceuticals and 2 mentions for Aquestive Therapeutics. ANI Pharmaceuticals' average media sentiment score of 0.67 beat Aquestive Therapeutics' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ANI Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ANI Pharmaceuticals currently has a consensus target price of $105.83, indicating a potential upside of 39.82%. Aquestive Therapeutics has a consensus target price of $8.50, indicating a potential upside of 93.84%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aquestive Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

ANI Pharmaceuticals has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$923.71M	1.86	$78.34M	$4.64	16.31
Aquestive Therapeutics	$44.54M	12.35	-$83.78M	-$0.61	N/A

ANI Pharmaceuticals has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 8.1% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ANI Pharmaceuticals has a net margin of 11.07% compared to Aquestive Therapeutics' net margin of -137.08%. ANI Pharmaceuticals' return on equity of 27.37% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

ANI Pharmaceuticals beats Aquestive Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and Aquestive Therapeutics (NASDAQ:AQST) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Ocular Therapeutix has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Aquestive Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	39.04	-$265.94M	-$1.42	N/A
Aquestive Therapeutics	$44.54M	12.35	-$83.78M	-$0.61	N/A

In the previous week, Ocular Therapeutix had 17 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 19 mentions for Ocular Therapeutix and 2 mentions for Aquestive Therapeutics. Ocular Therapeutix's average media sentiment score of 0.02 beat Aquestive Therapeutics' score of 0.00 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ocular Therapeutix currently has a consensus target price of $25.75, suggesting a potential upside of 178.83%. Aquestive Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 93.84%. Given Ocular Therapeutix's higher probable upside, research analysts clearly believe Ocular Therapeutix is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	2 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.69
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aquestive Therapeutics has a net margin of -137.08% compared to Ocular Therapeutix's net margin of -579.10%. Aquestive Therapeutics' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Summary

Ocular Therapeutix beats Aquestive Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Trulieve Cannabis?

Aquestive Therapeutics (NASDAQ:AQST) and Trulieve Cannabis (NYSE:TRLV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Trulieve Cannabis has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Trulieve Cannabis	N/A	N/A	N/A

Aquestive Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 93.84%. Trulieve Cannabis has a consensus price target of $15.00, indicating a potential upside of 67.17%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Trulieve Cannabis had 12 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 14 mentions for Trulieve Cannabis and 2 mentions for Aquestive Therapeutics. Trulieve Cannabis' average media sentiment score of 0.05 beat Aquestive Therapeutics' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Trulieve Cannabis	0 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	4 Negative mention(s)	1 Very Negative mention(s)	Neutral

Trulieve Cannabis has lower revenue, but higher earnings than Aquestive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$44.54M	12.35	-$83.78M	-$0.61	N/A
Trulieve Cannabis	N/A	N/A	N/A	N/A	N/A

32.5% of Aquestive Therapeutics shares are held by institutional investors. 6.8% of Aquestive Therapeutics shares are held by insiders. Comparatively, 3.8% of Trulieve Cannabis shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Aquestive Therapeutics beats Trulieve Cannabis on 7 of the 11 factors compared between the two stocks.

How does Aquestive Therapeutics compare to Innoviva?

Innoviva (NASDAQ:INVA) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Innoviva has higher revenue and earnings than Aquestive Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	3.71	$271.17M	$4.10	5.05
Aquestive Therapeutics	$44.54M	12.35	-$83.78M	-$0.61	N/A

Innoviva has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market.

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are owned by institutional investors. 2.0% of Innoviva shares are owned by company insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Innoviva has a net margin of 81.19% compared to Aquestive Therapeutics' net margin of -137.08%. Innoviva's return on equity of 28.03% beat Aquestive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	81.19%	28.03%	20.19%
Aquestive Therapeutics	-137.08%	N/A	-49.33%

Innoviva presently has a consensus price target of $36.80, indicating a potential upside of 77.79%. Aquestive Therapeutics has a consensus price target of $8.50, indicating a potential upside of 93.84%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aquestive Therapeutics is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Innoviva had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 8 mentions for Innoviva and 2 mentions for Aquestive Therapeutics. Innoviva's average media sentiment score of 0.17 beat Aquestive Therapeutics' score of 0.00 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Innoviva beats Aquestive Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Aquestive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AQST vs. The Competition

Export

Metric	Aquestive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$547.68M	$11.88B	$7.03B	$12.96B
Dividend Yield	N/A	2.69%	2.58%	10.20%
P/E Ratio	-7.16	788.46	269.91	24.87
Price / Sales	12.35	969.81	654.69	108.21
Price / Cash	N/A	15.12	28.89	37.44
Price / Book	-15.66	10.37	11.40	6.45
Net Income	-$83.78M	$2.77B	$3.45B	$347.50M
7 Day Performance	15.70%	2.26%	3.66%	3.77%
1 Month Performance	6.43%	-1.28%	-0.49%	-0.40%
1 Year Performance	12.44%	191.26%	77.51%	23.55%

Aquestive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AQST Aquestive Therapeutics	1.6243 of 5 stars	$4.50 +14.1%	$8.50 +89.1%	+1.0%	$562.73M	$44.54M	N/A	160	News Coverage Upcoming Earnings Gap Up
URGN Urogen Pharma	2.5618 of 5 stars	$38.29 -6.8%	$41.63 +8.7%	+164.6%	$1.86B	$109.79M	N/A	200	Earnings Report Analyst Revision
ANIP ANI Pharmaceuticals	4.2992 of 5 stars	$79.23 -1.5%	$105.00 +32.5%	-4.0%	$1.81B	$883.37M	20.11	600	Positive News Earnings Report Analyst Downgrade
OCUL Ocular Therapeutix	2.6857 of 5 stars	$8.20 -3.2%	$25.11 +206.4%	-24.7%	$1.79B	$51.95M	N/A	230	Earnings Report Analyst Upgrade
TRLV Trulieve Cannabis	3.2988 of 5 stars	$8.57 -0.1%	$15.00 +75.1%	N/A	$1.65B	$1.17B	N/A	9,000	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AQST) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aquestive Therapeutics (AQST) Competitors

AQST vs. URGN, ANIP, OCUL, TRLV, and INVA

How does Aquestive Therapeutics compare to Urogen Pharma?

Summary

How does Aquestive Therapeutics compare to ANI Pharmaceuticals?

Summary

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Summary

How does Aquestive Therapeutics compare to Trulieve Cannabis?

Summary

How does Aquestive Therapeutics compare to Innoviva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aquestive Therapeutics (AQST) Competitors

AQST vs. URGN, ANIP, OCUL, TRLV, and INVA

How does Aquestive Therapeutics compare to Urogen Pharma?

Does the media favor AQST or URGN?

Is AQST or URGN more profitable?

Which has higher valuation and earnings, AQST or URGN?

Do insiders and institutionals hold more shares of AQST or URGN?

Do analysts prefer AQST or URGN?

Which has more volatility and risk, AQST or URGN?

Summary

How does Aquestive Therapeutics compare to ANI Pharmaceuticals?

Does the media prefer ANIP or AQST?

Do analysts rate ANIP or AQST?

Which has better valuation & earnings, ANIP or AQST?

Which has more risk & volatility, ANIP or AQST?

Do insiders & institutionals have more ownership in ANIP or AQST?

Is ANIP or AQST more profitable?

Summary

How does Aquestive Therapeutics compare to Ocular Therapeutix?

Which has more volatility and risk, OCUL or AQST?

Which has stronger valuation & earnings, OCUL or AQST?

Does the media prefer OCUL or AQST?

Do analysts prefer OCUL or AQST?

Do insiders and institutionals hold more shares of OCUL or AQST?

Is OCUL or AQST more profitable?

Summary

How does Aquestive Therapeutics compare to Trulieve Cannabis?

Is AQST or TRLV more profitable?

Do analysts prefer AQST or TRLV?

Does the media prefer AQST or TRLV?

Which has higher earnings & valuation, AQST or TRLV?

Do insiders & institutionals believe in AQST or TRLV?

Summary

How does Aquestive Therapeutics compare to Innoviva?

Which has better valuation & earnings, INVA or AQST?

Which has more risk and volatility, INVA or AQST?

Do insiders and institutionals believe in INVA or AQST?

Is INVA or AQST more profitable?

Do analysts rate INVA or AQST?

Does the media refer more to INVA or AQST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST vs. The Competition

Aquestive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools